Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (111)

« Back to Publications

Menin inhibitors: a 2-in-1 defense versus AML immune evasion.

Chakraverty R., (2026), Blood, 147, 482 - 483

Advancing the Integration of 'Basic/Fundamental' and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress.

McLornan DP. et al, (2025), Bone Marrow Transplant, 60, 1303 - 1308

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.

Zeiser R. et al, (2025), J Clin Oncol, 43, 2566 - 2571

Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus study.

Hughes SE. et al, (2025), EClinicalMedicine, 84

Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial).

Chakraverty R. et al, (2025), BMJ Open, 15

Stem cell transplantation

Craddock C. and Chakraverty R., (2025), 719 - 744

Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies.

Khatsuria F. et al, (2024), Lancet Oncol, 25, e476 - e488

How Important Is Unrelated Donor Human Leukocyte Antigen Disparity in the Post-Transplant Cyclophosphamide Era?

Chakraverty R., (2024), J Clin Oncol, 42, 3263 - 3265

Integrating patient and public involvement and engagement in translational medicine.

Shaw KL. et al, (2024), Lancet, 404, 828 - 831

Predictive Performance of Cardiovascular Risk Scores in Cancer Survivors From the UK Biobank.

McCracken C. et al, (2024), JACC CardioOncol, 6, 575 - 588

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.

Goodyear CS. et al, (2024), Lancet Rheumatol, 6, e339 - e351

The road to refractory graft-versus-host disease is paved with good intentions.

North D. and Chakraverty R., (2024), J Clin Invest, 134

ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission.

Marks DI. et al, (2023), BMJ Open, 13

Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity.

Cheminant M. et al, (2023), Blood, 141, 60 - 71

Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.

Schetelig J. et al, (2022), Bone Marrow Transplant, 57

Load More

1
2
3
4
5
6
7
...
»